| Q38760623 | A catalogue of treatment and technologies for malignant pleural mesothelioma |
| Q85609708 | Advanced diffuse malignant peritoneal mesothelioma responding to palliative chemotherapy |
| Q37070229 | Advances in the systemic therapy of malignant pleural mesothelioma |
| Q38800916 | Advances in treatment of mesothelioma. |
| Q30478994 | BTS statement on malignant mesothelioma in the UK, 2007. |
| Q80952804 | Case report: malignant peritoneal mesothelioma in two siblings |
| Q61051793 | Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma |
| Q36429607 | Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent |
| Q59132464 | Current chemotherapy strategies in malignant pleural mesothelioma |
| Q28393560 | Current issues in malignant pleural mesothelioma evaluation and management |
| Q37232309 | Current therapies for malignant pleural mesothelioma |
| Q88875732 | Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma |
| Q46548604 | Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma |
| Q43724326 | Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q33378691 | Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma |
| Q37052430 | Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study |
| Q37457703 | Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230. |
| Q30429528 | Malignant pleural mesothelioma: comparison of radical pleurectomy und extrapleural pneumonectomy |
| Q37529848 | Malignant pleural mesothelioma: current treatments and emerging drugs. |
| Q26821919 | Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health |
| Q37277434 | Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG). |
| Q57822522 | Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy |
| Q36830116 | Management options for malignant pleural mesothelioma: clinical and cost considerations |
| Q37866663 | Medical treatment of mesothelioma: anything new? |
| Q37201356 | Mesothelioma and asbestos-related pleural diseases |
| Q29248127 | Modern management of malignant pleural mesothelioma |
| Q88649792 | NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial |
| Q33890499 | Novel systemic therapy against malignant pleural mesothelioma |
| Q50168144 | Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. |
| Q34091240 | Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. |
| Q82235520 | Peritoneal mesothelioma |
| Q39260316 | Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy |
| Q36425940 | Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma |
| Q43132169 | Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed |
| Q36822893 | Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma |
| Q51541835 | SEOM guidelines for the treatment of malignant pleural mesothelioma. |
| Q42864235 | Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006) |
| Q46807402 | Standard therapy for the treatment of malignant pleural mesothelioma |
| Q61812961 | Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment |
| Q38586323 | Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. |
| Q37992694 | Systemic treatment of malignant pleural mesothelioma |
| Q35129531 | Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. |
| Q82061962 | [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma] |